Background/Aims: To identify physician selection factors in the treatment of locally advanced head and neck cancer and how treatment outcome is affected by Tumor Board recommendations. Methods: A retrospective analysis of 213 patients treated for locally advanced head and neck cancer in a single institution was performed. All treatments followed Tumor Board recommendations: 115 patients had chemotherapy and radiation, and 98 patients received postoperative radiation. Patient characteristics, treatment toxicity, locoregional control and survival between these two treat- ment groups were compared. Patient survival was compared with survival data reported in randomized studies of locally advanced head and neck cancer. Results: There were no differences in comorbidity factors, and T or N stages between the two groups. A statistically significant number of patients with oropharyngeal and oral cavity tumors had chemoradiation and postoperative radiation, respectively (p < 0.0001). Grade 3–4 toxicities during treatment were 48 and 87% for the postoperative radiation and chemoradiation groups, respectively (p = 0.0001). There were no differences in survival, locoregional recurrences and distant metastases between the two groups. Patient survival was comparable to survival rates reported by randomized studies of locally advanced head and neck cancer. Conclusion: Disease sites remained the key determining factor for treatment selection. Multidisciplinary approaches provided optimal treatment outcome for locally advanced head and neck cancer, with overall survival in these patients being comparable to that reported in randomized clinical trials.

Keywords:
Chemoradiation, Head and neck cancer, Postoperative radiation, Treatment selection, Tumor Board recommendations
1.
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000;50:636–639.
2.
Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler R: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 1991;20:21–28.
3.
Shah J, Lydiatt W: Treatment of cancer of the head and neck. CA Cancer J Clin 1995;45:352–368.
4.
Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brocstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE: Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961–1969.
5.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison U, Glisson B, Trotti A, Ridge JA, Chao C, Peters J, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–2098.
6.
Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson S, Greenberg MJ, Weinstein GS, Aviles VM, Chalian AA, Weber RS: Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002;20:3964–3971.
7.
Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Bhadimipati PV, Karlsson U, Nguyen PD, Alfieri A, Nguyen LM, Lemanski C, Chan W, Rose S, Sallah S: Aspiration rate following chemoradiation for head and neck cancer, an underreported occurrence. Radiother Oncol 2006;80:302–306.
8.
Mick R, Lane N, Dauherty C, Ratain MJ: Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J National Cancer Inst 1994;22:1685–1693.
9.
Redeimeier DA, Shafir E: Medical decision making in situations that offer multiple alternatives. JAMA 1995;273:302–305.
10.
Abdallah I, Basu A, Hellman S: An evidence-based analysis of the management of localized prostate cancer. Cancer J 2002;8:40–46.
11.
Bowman CC, Lennox PA, Clugston PA, Courtemanche DJ: Breast reconstruction in older women: should age be an exclusion criterion? Plastic Reconstr Surg 2006;118:16–22.
12.
Gourin CG, McAfee WJ, Neyman KM, Howington JW, Podolsky RH, Terris DJ: Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:1371–1375.
13.
Castro MAF, Dedivitis RA, Ribeiro KCB: Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL 2007;69:146–152.
14.
Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MR, Kowalski LP: Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007;14:1449–1457.
15.
Gleich LL, Collins M, Gartside PS, Gluckman JL, Barrett WL, Wilson KM, Biddinger PW, Redmond KP: Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:26–35.
16.
Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, Har-El G, Lucente FE: Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck 1998;20:1–7.
17.
Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J, Fan CY, Breau R, Suen J: Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck. Arch Otolaryngol Head Neck Surg 2004;130:861–867.
18.
Madan AK, Aliabadi-Wahle S, Beech DJ: Age bias: a cause of underutilization of breast conservation treatment. J Cancer Educ 2001;16:29–32.
19.
Janssen-Heijnen MLG, Maas HAA, Houterman S, Lemmens VEPP, Rutten HJT, Coeberg JWW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007;43:2179–2193.
20.
Harrison LB, Zelefsky MJ, Armstrong JG, Carper E, Gaynor JJ, Sessions RB: Performance status after treatment for squamous cell cancer of the base of tongue – a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys 1994;30:953–957.
21.
Parliament M, Alidrisi M, Munroe M, Wolfaardt J, Scrimger R, Thompson H, Field C, Kurien E, Hanson J: Implications of radiation dosimetry of the mandible in patients with carcinoma of the oral cavity and nasopharynx treated with intensity modulated radiation therapy. Int J Oral Maxillofac Surg 2005;34:114–121.
22.
Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA: An Intergroup phase III comparison of standard radiotherapy and two schedules of concurrent chemoradiotherapy in patients with unresectable head and neck cancer. J Clin Oncol 2003;21:92–98.
23.
Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, Goh C, Leong SS, Tan T, Fong KW, See A, Machin D: Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomized comparison. Br J Cancer 2005;93:279–286.
24.
Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenberg JL, de Vries EG: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analysis. J Dent Res 2006;85:690–700.
25.
Nguyen NP, Levinson B, Dutta S, Karlsson U, Kelly KC, Dowell J, Ludin A, Sallah S: Amifostine and curative intent chemoradiation for compromised cancer patients. Anticancer Res 2003;23:1649–1656.
26.
Posner MR, Hershock DM, Blajman CR, Mickiewiz EM, Winquist E, Gorbournova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tischler RB, Roth B, Viroglio RDC, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Crnelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–1715.
27.
Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L: Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22:3540–3548.
28.
Bartelink H, Van den Bogaert W, Horiot JC, Jager J, van Glabbeke M: Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. Eur J Cancer 2002;38:667–673.
29.
Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentze M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Biol Phys 2001;50:1161–1171.
30.
Zakotnik B, Budhina M, Smid L, Soba E, Strojan P, Fajdiga I, Zargi M, Oblak I, Lesnicar H: Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concurrent chemoradiation with mitomycin and bleomycin. Int J Radiat Biol Phys 2007;3:685–690.
31.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1397–1344.
32.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.